Moderna Inc
NASDAQ: MRNA
$38.36
-$2.40 (-5.9%)
Closing Price on December 18, 2024
MRNA Articles
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Published:
Independent research firm Argus has reiterated its Buy rating on Moderna and is calling this large pullback a buying opportunity.
Published:
When Moderna announced a new deal with the U.S. government for its COVID-19 vaccine, it appeared be a case of “sell the news,” because this is ultimately a net positive for the company.
Published:
Thursday's top analyst upgrades and downgrades included Costco, Enphase Energy, Etsy, Moderna, Novavax, Regeneron Pharmaceuticals, Roku, Square, Teva Pharmaceutical, Wayfair and Zynga.
Published:
Arbutus Biopharma stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontrunner Moderna.
Published:
Thursday's top analyst upgrades and downgrades included Apache, Check Point Software Technologies, Chipotle Mexican Grill, Electronic Arts, Inogen, Microsoft, Moderna, Shopify, Tesla and Varonis...
Published:
These four top Jefferies growth stock picks all offer investors strength in their specific industries and the ability to generate some significant portfolio alpha.
Published:
Stocks were looking for direction on Monday ahead of this week’s earnings deluge. With an election coming up and with what is still a very deep recession, investors need to be considering how they...
Published:
The number of COVID-19 cases continues to rise, which will only create more demand for coronavirus stocks. 24/7 Wall Street has picked out a few of the best and brightest that could still see a big...
Published:
Moderna made another big step forward in the fight against COVID-19 after the company reported incredibly positive data from the early-stage trial of its coronavirus vaccine.
Published:
Pfizer and BioNTech have progressed in their COVID-19 vaccine effort, according to the FDA. Two of the companies’ four coronavirus vaccine candidates received Fast Track Designation.
Published:
Monday's top analyst upgrades and downgrades included Alphabet, Amazon.com, Apple, Disney, DuPont, Halliburton, Moderna, Phillips 66, Sunrun, Teladoc and more.
Published:
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
Published:
Monday's top analyst upgrades and downgrades included American Express, Boeing, Coca-Cola, Dunkin' Brands, L Brands, Lululemon Athletica, Moderna, NXP Semiconductors, Seagate Technology, ViacomCBS...
Published:
Novavax shares jumped to start off the week after an update from its COVID-19 vaccine trial. This news adds to investor optimism and is helping to lift the broad markets in general.
Published: